Compare ACADIA Pharmaceuticals Inc. (ACAD) vs JD.Com Inc (JD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs JD.Com Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while JD.Com Inc trades at $27.54 (market cap $36.37B). The key difference: JD.Com Inc is far larger — about 8.1× ACADIA Pharmaceuticals Inc.'s market cap, and JD.Com Inc pays a 3.78% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | JD | |
|---|---|---|
Market Cap | $4.49B | $36.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $36.17 |
52-Week Low | $20.06 | $25.19 |
Enterprise Value | $3.69B | $22.53B |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
JD trades at $26.49, down 0.49% on the day, with a bearish technical signal and mixed sentiment. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 show operational strength, but net income margin compression to 1.05% in 2025 raises concerns. The stock appears undervalued with a P/S of 0.2 and P/E of 19.66, while analyst consensus remains strongly bullish with a $39.20 price target.
The outlook is cautiously optimistic given JD's low valuation and consistent earnings outperformance, but risks include legal investigations, margin pressure, and macroeconomic headwinds. Upside potential exists if the company can sustain revenue growth and improve profitability, though near-term volatility may persist due to negative news flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
